Regional focus

For DFU, Cutempa Medical Ltd. prioritizes regions with high unmet need and strong strategic relevance:

  • Europe
    First approval region and clinical anchor market
  • United States
    Largest advanced wound care market with strong partnering potential
  • China
    High patient numbers and dedicated market entry opportunity

 

 

 

 

Diabetes patients

DFU-prevalence (n)
 

Strategy



Current status

Opportunity

Europe

Diabetes patients

47 million

DFU

10%
(4.7 million patients)

Strategy

Product with different
surfactant to China (Curi01)
Central production for
Europe and USA

Current status

Preparing clinical trial

Opportunity

Clinical trial
as basis for European
and FDA approval

USA

Diabetes patients

43 million

DFU

15%
(6.5 million patients)

Strategy

Product with different
surfactant to China (Curi01)
Central production for
Europe and USA

Current status

Preparing clinical trial

Opportunity

Clinical trial
as basis for European
and FDA approval

China

Diabetes patients

115 million

DFU

8.1%
(9.7 million patients)

Strategy

Local product &
manufacturing (Curi02)

 

Current status

Ready to launch local clinical trial

Opportunity

De-risking EU-trial
China approval possible